AIxCrypto (AIXC) Stock Analysis

What AIxCrypto does

AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.

Key metrics

ETFs linked to AIXC

Broad-market and Technology sector ETFs an investor holding AIxCrypto is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AIXC fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for AIxCrypto?

AIxCrypto trades under the ticker AIXC on NASDAQ.

Which exchange is AIXC listed on?

AIXC is listed on NASDAQ.

What sector does AIxCrypto operate in?

AIxCrypto is classified in the Technology sector (Software - Infrastructure industry).

How can PortView help analyze AIXC in a portfolio?

PortView shows AIXC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.